Vol 6, No 2 (2020)
Research paper
Published online: 2020-07-09
Page views 789
Article views/downloads 40
Get Citation

Connect on Social Media

Connect on Social Media

Efficacy and safety of 0.1% Tacrolimus ointment versus 0.05% Clobetasone butyrate ointment in childhood atopic dermatitis

Sanjoy Prasad Das1, Mohammad Rafiqul Mowla1, Deva Pratim Barua1, Selim Mohammed Jahangir2, Ismail Khan3
Forum Dermatologicum 2020;6(2):33-39.


Introduction: Atopic dermatitis (AD) is a chronic relapsing skin condition characterized by intense itching, dry skin, redness, in_ammation and exudation with signi_cant morbidity. It often requires long-term use of topical corticosteroids but, patients’ adherence to corticosteroids may be limited by perceived risks and systemic adverse e_ects. Therefore, steroid-sparing topical agent is needed. To compare the e_cacy and safety of 0.1% tacrolimus ointment and 0.05% clobetasone butyrate ointment in patients with childhood AD. 

Materials and methods: This monocentric prospective open-label comparative study was carried out in the Department of Dermatology and Venereology, Chittagong Medical College Hospital. Two hundred patients of 2–10 years of age with mild to moderate AD involving _ 50% of the total body surface area (BSA) were randomly assigned. The treatment duration was 4 weeks and was followed-up for 12 weeks. The eczema area and severity index (EASI) and the physician’s global evaluation of clinical response were assessed and evaluated. 

Results: E_ective sample size was 176 as because 24 patients were dropped out during follow up. EASI score was signi_cantly changed from baseline in follow up weeks and there was a statistically signi_cant di_erence in the reduction of EASI of patients in Tacrolimus groups at the end of 2nd week, 4th week, 6th week than the other group (p < 0.05). At the end of 4 weeks treatment, a median improvement of _ 75% in EASI was observed in 86% and 57% of patients in Tacrolimus and Clobetasone Group, respectively. At the end of the 12 week follow-up period, these improvements persist. Both the regimens were well tolerated.

Conclusions: The overall therapeutic e_ectiveness was in favour of topical Tacrolimus ointment (0.1%) over topical Clobetasone butyrate ointment (0.05%) for the treatment of AD in children. 

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?


  1. Patrizi A, Pileri A, Bellini F, et al. Atopic Dermatitis and the Atopic March: What Is New? Journal of Allergy. 2011; 2011: 1–5.
  2. Eczema (dermatitis). Common Skin Diseases 18th edition. 2013: 114–137.
  3. Hebert A. 2010 (July/August). Mild to Moderate Atopic dermatitis: A guide to therapeutic selection, Practical Dermatology for paediatrics. : 37.
  4. Dhar S. Atopic Dermatitis. Textbook of Pediatric Dermatology. 2014: 112–112.
  5. Systematic review of treatments for atopic eczema. Health Technology Assessment. 2000; 4(37).
  6. Tacrolimus Ointment. 2004.
  7. Morley N, Fry L, Walker S. Clinical evaluation of clobetasone butyrate in the treatment of children with atopic eczema, and its effect on plasma corticosteroid levels. Current Medical Research and Opinion. 2008; 4(3): 223–228.
  8. Williams HC, Pembroke AC, Forsdyke H, et al. London-born black caribbean children are at increased risk of atopic dermatitis. Journal of the American Academy of Dermatology. 1995; 32(2): 212–217.
  9. Baldo A, Baldo A. Tacrolimus ointment in the management of atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology. 2009: 1.
  10. Paller A, Eichenfield L, Leung D, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology. 2001; 44(1): S47–S57.
  11. Remitz A, Kyllönen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. Journal of Allergy and Clinical Immunology. 2001; 107(1): 196–197.
  12. Adherence to topical tacrolimus 0.1% ointment in children with atopic dermatitis. Journal of the American Academy of Dermatology. 2010; 62(3): AB46.
  13. Atopic Dermatitis. Animal Models of Human Inflammatory Skin Diseases. 2013: 351–351.
  14. BOGUNIEWICZ M. Current management of atopic dermatitis and interruption of the atopic march. Journal of Allergy and Clinical Immunology. 2003; 112(6): S140–S150.
  15. Ruzicka T. Atopic Eczema Between Rationality and Irrationality. Archives of Dermatology. 1998; 134(11).
  16. Reitamo S. Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis. Journal of Allergy and Clinical Immunology. 2001; 107(3): 445–448.
  17. UK pharma contributes £1 billion for new NHS drugs. PharmacoEconomics & Outcomes News. 2016; 749(1): 36–36.
  18. Simpson E, Hanifin J. Atopic dermatitis. Journal of the American Academy of Dermatology. 2005; 53(1): 115–128.
  19. Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. Allergology International. 2017; 66(2): 230–247.
  20. Lassus A. Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison. Current Medical Research and Opinion. 2008; 6(3): 165–167.
  21. FK 506. SpringerReference. .